Neuroendocrine Tumors in Children and Young Adults: Rare or Not So Rare

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 1, 2011, Pages 65-80

  Sarvida, Marie Ellen ^a   O'Dorisio, M Sue ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Carcinoid; Multiple endocrine neoplasia; Neuroblastoma; Neuroendocrine tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; CORTICOTROPIN; DOCETAXEL; DOXORUBICIN; GROWTH HORMONE RELEASING FACTOR; LUTETIUM 177; OCTREOTIDE; PLATINUM DERIVATIVE; RADIOISOTOPE; TAXANE DERIVATIVE; TEMOZOLOMIDE; YTTRIUM 90;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; COLON NEUROENDOCRINE TUMOR; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOSIMETRY; EWING SARCOMA; GENE OVEREXPRESSION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; INSULINOMA; MELANOMA; MOLECULAR DIAGNOSIS; NEURAL CREST; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTAL NEUROENDOCRINE TUMOR; REVIEW; SMALL CELL CARCINOMA; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADOLESCENT MEDICINE; ADULT; AGE OF ONSET; CHILD; GASTROINTESTINAL NEOPLASMS; GEOGRAPHY; HUMANS; INCIDENCE; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEDIATRICS; YOUNG ADULT;

EID: 79951750941     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.12.007     Document Type: Review

References (71)

1. Navalkele P., O'Dorisio M.S., O'Dorisio T.M. Incidence, survival and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011, 56(1):50-57.
2. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
3. Hauso O., Gustafsson B.I., Kidd M., et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008, 113(10):2655-2664.
4. Hegde V., Mohandas K.M., Ramadwar M., et al. Gastric carcinoids-a changing trend. Indian J Gastroenterol 2003, 22:209-211.
5. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
6. Taal B.G., Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004, 80(Suppl 1):3-7.
7. Rangiah D.S., Cox M., Richardson M., et al. Small bowel tumours: a 10 year experience in four Sydney teaching hospitals. ANZ J Surg 2004, 74:788-792.
8. Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001, 92:2204-2210.
9. Westergaard T., Frisch M., Melbye M. Carcinoid tumors in Denmark 1978-1989 and the risk of subsequent cancers. A population-based study. Cancer 1995, 76:106-109.
10. Crocetti E., Buiatti E., Amorosi A. Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997, 13:357-359.
11. Newton J.N., Swerdlow A.J., dos Santos Silva I.M., et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994, 70:939-942.
12. Younes R.N. Neuroendocrine tumors: a registry of 1,000 patients. Rev Assoc Med Bras 2008, 54:305-307.
13. Ploeckinger U., Kloeppel G., Wiedenmann B., et al. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009, 90:349-363.
14. Levi F., Randimbison L., Franceschi S., et al. Descriptive epidemiology of malignant carcinoids in the Swiss Canton of Vaud. Int J Cancer 1993, 53:1036-1037.
15. Ito T., Sasano H., Tanaka M., et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010, 45:234-243.
16. Lepage C., Ciccolallo L., De Angelis R., et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer 2010, 126(12):2928-2934.
17. Bloom D., Canning D., Sevilla J. The effect of health on economic growth: a production function approach. World Dev 2004, 32:1-13.
18. Hassan M.M., Phan A., Li D., et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer 2008, 123:867-873.
19. Corpron C.A., Black C.T., Herzog C.E., et al. A half century of experience with carcinoid tumors in children. Am J Surg 1995, 170:606-608.
20. Ladd A.P., Grosfeld J.L. Gastrointestinal tumors in children and adolescents. Semin Pediatr Surg 2006, 15:37-47.
21. Broaddus R.R., Herzog C.E., Hicks M.J. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 2003, 127:1200-1203.
22. Khanna G., O'Dorisio M.S., Menda Y., et al. Gastroenteropancreatic neuroendocrine tumors in children and young adults. Pediatr Radiol 2008, 38:251-259.
23. Parham D.M. Neuroectodermal and neuroendocrine tumors principally seen in children. Am J Clin Pathol 2001, 115(Suppl):S113-S128.
24. Spunt S.L., Pratt C.B., Rao B.N., et al. Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. J Pediatr Surg 2000, 35:1282-1286.
25. Modlin I.M., Champaneria M.C., Bornschein J., et al. Evolution of the diffuse neuroendocrine system-clear cells and cloudy origins. Neuroendocrinology 2006, 84:69-82.
26. Papotti M., Rosas R., Longo M., et al. Pathologica 2005, 97:215. [in Italian].
27. Vinik A., Moattari A.R. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989, 34:14S-27S.
28. Gustafsson B.I., Kidd M., Chan A., et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113:5-21.
29. Klimstra D.S., Modlin I.R., Adsay N.V., et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010, 34:300-313.
30. Phan A.T., Oberg K., Choi J., et al. NANETS concensus guideline for the diagnosis and management of neuroendocrine tumors: well-defined neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010, 39(6):784-798.
31. Clark O.H., Benson A.B., Berlin J.D., et al. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009, 7:712-747.
32. van E.M., Krenning E.P., Bakker W.H., et al. Peptide receptor radionuclide therapy with (177)Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007, 34(8):1219-1227.
33. Bushnell D.L., O'Dorisio T.M., O'Dorisio M.S., et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010, 28(10):1652-1659.
34. Kleer C.G. Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions. Arch Pathol Lab Med 2009, 133:1822-1825.
35. Sasaki Y., Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009, 16:254-259.
36. Rakha E.A., Aleskandarany M., El-Sayed M.E., et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009, 45:1780-1787.
37. Skinner M.A., Moley J.A., Dilley W.G., et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005, 353:1105-1113.
38. Calva D., O'Dorisio T.M., Sue O'Dorisio M., et al. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?. Ann Surg Oncol 2009, 16:2237-2244.
39. Boudreaux J.P., Putty B., Frey D.J., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005, 241:839-845.
40. Giusti M., Sidoti M., Augeri C., et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004, 150:299-303.
41. Glaser B., Landau H., Smilovici A., et al. Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin. Clin Endocrinol (Oxf) 1989, 31:71-80.
42. Manabe M., Morimatsu H., Egi M., et al. Masui 2009, 58:757-759. [in Japanese].
43. Lodish M.B., Powell A.C., Abu-Asab M., et al. Insulinoma and gastrinoma syndromes from a single intrapancreatic neuroendocrine tumor. J Clin Endocrinol Metab 2008, 93:1123-1128.
44. Bonfig W., Kann P., Rothmund M., et al. Recurrent hypoglycemic seizures and obesity: delayed diagnosis of an insulinoma in a 15 year-old boy-final diagnostic localization with endosonography. J Pediatr Endocrinol Metab 2007, 20:1035-1038.
45. Bax K.N., van der Zee D.C. The laparoscopic approach toward hyperinsulinism in children. Semin Pediatr Surg 2007, 16:245-251.
46. de Vogelaere K., De Schepper J., Vanhoeij M., et al. Laparoscopic management of insulinoma in a child with multiple endocrine neoplasia type 1. J Laparoendosc Adv Surg Tech A 2006, 16:335-338.
47. Karachaliou F., Vlachopapadopoulou E., Kaldrymidis P., et al. Malignant insulinoma in childhood. J Pediatr Endocrinol Metab 2006, 19:757-760.
48. Menda Y., O'Dorisio M.S., Kao S., et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010, 51(10):1524-1531.
49. Rindi G., Kloppel G., Couvelard A., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
50. Anthony L.B., Strosberg J.R., Klimstra D.S., et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated NETs of the distal colon and rectum. Pancreas 2010, 39:767-774.
51. Vinik A.I., Anthony L., Boudreaux J.P., et al. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas 2010, 39(6):801-818.
52. Prasad V, Kaemmerer D, Hommann M, et al. Management of neuroendocrine tumors of the rectum (rNET) using Ga-68 somatostatin receptor PET/CT (SR-PET/CT) and Peptide Receptor Radionuclide Therapy (PRRT). Proceedings: 6th Annual European Neuroendocrine Tumor Society (ENETS) Conference. Granada (Spain), March 5-7, 2009.
53. Martinez-Borges A.R., Petty J.K., Hurt G., et al. Familial small cell carcinoma of the ovary. Pediatr Blood Cancer 2009, 53:1334-1336.
54. Christin A., Lhomme C., Valteau-Couanet D., et al. Successful treatment for advanced small cell carcinoma of the ovary. Pediatr Blood Cancer 2008, 50:1276-1277.
55. Shrimali R.K., Correa P.D., Reed N.S. Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature. Med Oncol 2010, 1-5. [Epub ahead of print].
56. Fanti S., Ambrosini V., Tomassetti P., et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008, 62:667-671.
57. Khanna G., Bushnell D., O'Dorisio M.S. Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist 2008, 13(4):382-389.
58. Juweid M.E., Menda Y., O'Dorisio M.S., et al. 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma. Nucl Med Commun 2002, 23:983-989.
59. Baum R.P., Prasad V., Hommann M., et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008, 170:225-242.
60. Starker L.F., Carling T. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol 2009, 21:29-33.
61. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009, 16:72-78.
62. Drozdov I., Kidd M., Nadler B., et al. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009, 115:1638-1650.
63. August J. Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov 2010, 9:351.
64. Schork N.J., Topol E.J. Genotype-based risk and pharmacogenetic sampling in clinical trials. J Biopharm Stat 2010, 20:315-333.
65. Chen S., Chen J., Ma G., et al. Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma. Am J Clin Oncol 2011, [Epub ahead of print].
66. Kwekkeboom D.J., de Herder W.W., van Eijck C.H., et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010, 40:78-88.
67. Otte A., Jermann E., Behe M., et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997, 24:792-795.
68. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
69. Waldherr C., Pless M., Maecke H.R., et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941-945.
70. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005, 46(Suppl 1):62S-66S.
71. Bodei L., Cremonesi M., Ferrari M., et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008, 35:1847-1856.